Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thinking about a move from academia to industry? Look before you leap.

Nature biotechnology·2025

Same author

Academic entrepreneurship: promise and perils.

Trends in biotechnology·2025

Same author

Is ASCT2 a Suitable Vector for the Selective Delivery of Anticancer Drugs? Modification of Glutamine at Either the Carboxylate or the Side Chain Hinders Binding and Transport.

ChemMedChem·2024

Same author

Platinum binding preferences dominate the binding of novel polyamide amidine anthraquinone platinum(II) complexes to DNA.

Dalton transactions (Cambridge, England : 2003)·2021

Same author

A primer for academic entrepreneurs on academic-industrial partnerships.

Nature communications·2021

Same author

Warburg Effect Targeting Co(III) Cytotoxin Chaperone Complexes.

Journal of medicinal chemistry·2021

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Targeted cancer therapeutics.

William N Hait¹, Trevor W Hambley

¹Division of Johnson and Johnson, Ortho Biotech Oncology Research and Development, Raritan, New Jersey 08869, USA. WHait@ITS.JNJ.COM

Cancer Research

|February 12, 2009

Summary

This summary is machine-generated.

Targeted cancer therapies attack specific cancer cell targets with lower toxicity, while nontargeted therapies affect broader cellular processes, often with higher toxicity. Future advances will enhance targeted therapy effectiveness, especially for solid tumors.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Experiment Videos

Last Updated: Jun 25, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Area of Science:

Oncology
Pharmacology
Molecular Biology

Background:

Cancer therapies are broadly classified into targeted and nontargeted approaches.
Targeted therapies are designed against specific molecular targets crucial for cancer cell function.
Nontargeted therapies are identified through phenotypic screening and often affect fundamental cellular processes.

Purpose of the Study:

To differentiate between targeted and nontargeted cancer therapies.
To discuss the efficacy, toxicity, and applications of each therapy type.
To explore future directions in the development of targeted cancer therapies.

Main Methods:

Review of existing literature and definitions of targeted and nontargeted therapies.
Comparative analysis of their mechanisms of action, toxicity profiles, and clinical efficacy.
Discussion of future trends based on advancements in related scientific fields.

Main Results:

Targeted therapies offer selective inhibition of cancer-specific targets with generally lower toxicity.
Nontargeted therapies, while effective, often exhibit significant toxicity due to their broader mechanisms.
Targeted therapies show high efficacy in hematologic malignancies but limited success in solid tumors, unlike nontargeted drugs.
Nontargeted drugs represent some of the most effective yet toxic agents in cancer treatment.

Conclusions:

Future advancements in genomics, proteomics, and drug design will drive the development of more selective and effective targeted therapies.
Identifying predictive biomarkers and understanding drug resistance mechanisms are crucial for optimizing targeted therapy outcomes.
A comprehensive understanding of drug targets is essential for designing effective combination therapies and overcoming resistance.